Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XOMA 052 · 6 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| XOMA 052 | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| 1 | ACTIVE_COMPARATOR | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| XOMA 052 | DRUG | 0.3 mg/kg XOMA 052. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections |
| Placebo | DRUG | 0.3 mg/kg Placebo. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections |
Inclusion Criteria: * Diagnosed with T2D (disease duration \>= 6 months) * HbA1c measurements \>= 7.0% and \<= 10.0% * On a stable regimen of metformin monotherapy * Age \>= 18 and \<= 75 * Stable diet and exercise regimen * BMI \<= 40 kg/m2 Exclusion Criteria: * Significant signs and symptoms of...
XOMA 052 is an investigational small molecule being studied for the treatment of type 1 diabetes and type 2 diabetes mellitus. It has been evaluated in Phase 2 clinical trials in adults with these metabolic conditions, including studies of its effects on insulin production and its safety and biologic activity.
XOMA 052 targets interleukin-1 beta, or IL-1 beta, a cytokine involved in inflammatory signaling. By binding this cytokine target, the small molecule is designed to modulate IL-1 beta activity, which researchers have studied in the context of diabetes. IL-1 beta is part of the broader cytokine class of molecular targets.
XOMA 052 is being developed by XOMA Royalty Corporation, which trades under the ticker XOMA. The company is the sponsor associated with the clinical development of this small molecule asset in metabolic indications.
XOMA 052 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. Its completed Phase 2 studies enrolled adults with type 1 or type 2 diabetes, and no trials are currently listed as active.
XOMA 052 has been studied in completed Phase 2 trials including NCT01788033 in type 1 diabetes in Switzerland, NCT00998699 in well controlled type 1 diabetes, NCT01144975 in type 2 diabetes in Mexico, and NCT01066715 in type 2 diabetes on stable metformin monotherapy in the United States.
Across its clinical trials, XOMA 052 has enrolled a total of 497 participants. The largest study, NCT01066715, enrolled 421 subjects with type 2 diabetes mellitus on stable metformin monotherapy, while the type 1 diabetes studies each enrolled 22 participants.